Low doses of the carbonic anhydrase inhibitor acetazolamide provides accelerated acclimatization to high-altitude hypoxia and prevention of cerebral and other symptoms of acute mountain sickness. We previously observed increases in cerebral O2 metabolism (CMRO 2 ) during hypoxia. In this study, we investigate whether low-dose oral acetazolamide (250 mg) reduces this elevated CMRO 2 and in turn might improve cerebral tissue oxygenation (PtiO 2 ) during acute hypoxia. Six normal human subjects were exposed to 6 h of normobaric hypoxia with and without acetazolamide prophylaxis. We determined CMRO 2 and cerebral PtiO 2 from MRI measurements of cerebral blood flow (CBF) and cerebral venous O2 saturation. During normoxia, low-dose acetazolamide resulted in no significant change in CBF, CMRO 2 , or PtiO 2 . During hypoxia, we observed increases in CBF [48.5 (SD 12.4 [6.92 (1.45) (hypoxia) to 5.60 (1.14) mmol/min (hypoxia ϩ acetazolamide), P Ͻ 0.05]. The net effect was improved cerebral tissue Pti O 2 during acute hypoxia [11.4 (2.7) (hypoxia) to 16.5 (3.0) mmHg (hypoxia ϩ acetazolamide), P Ͻ 0.05]. In addition to its renal effect, low-dose acetazolamide is effective at the capillary endothelium, and we hypothesize that local interruption in cerebral CO 2 excretion accounts for the improvements in CMR O 2 and ultimately in cerebral tissue oxygenation during hypoxia. This study suggests a potentially pivotal role of cerebral CO 2 and pH in modulating CMRO 2 and PtiO 2 during acute hypoxia. cerebral oxygen metabolism; cerebral oxygenation; cerebral blood flow; acetazolamide; hypoxia; magnetic resonance imaging ACUTE EXPOSURE TO HYPOXIA at high altitude can induce symptoms of acute mountain sickness (AMS). Acclimatization to hypoxia is accelerated and AMS can be prevented by prophylactic treatment with the carbonic anhydrase inhibitor acetazolamide (reviewed by Ref. 37). One intriguing effect of acetazolamide is a small (ϳ 5%) reduction in whole body oxygen consumption (V O 2 ) in both human and animal studies (5, 18, 31, 40) and similar effects on cerebral O 2 metabolism (CMR O 2 ) (49). These studies focused on high-dose acetazolamide (typically 750 -1,000 mg) that achieves almost complete inhibition of carbonic anhydrase. While the primary effect of acetazolamide is on acid base balance by producing a mild renal metabolic acidosis and an increase in ventilation (22), it also inhibits carbonic anhydrase in a dose-dependent fashion at other sites throughout the body, which might have additional effects related to high-altitude adaptation (37, 38). Considerably lower dose acetazolamide (250 mg) in which there is only selective or partial inhibition of carbonic anhydrase activities is effective to prevent AMS (1, 19, 24, 42) ; thus complete blockade of all carbonic anhydrase activity (from high-dose acetazolamide) is not required to achieve clinical benefit.
and similar effects on cerebral O 2 metabolism (CMR O 2 ) (49) . These studies focused on high-dose acetazolamide (typically 750 -1,000 mg) that achieves almost complete inhibition of carbonic anhydrase. While the primary effect of acetazolamide is on acid base balance by producing a mild renal metabolic acidosis and an increase in ventilation (22) , it also inhibits carbonic anhydrase in a dose-dependent fashion at other sites throughout the body, which might have additional effects related to high-altitude adaptation (37, 38) . Considerably lower dose acetazolamide (250 mg) in which there is only selective or partial inhibition of carbonic anhydrase activities is effective to prevent AMS (1, 19, 24, 42) ; thus complete blockade of all carbonic anhydrase activity (from high-dose acetazolamide) is not required to achieve clinical benefit.
In recent studies we observed increases in CMR O 2 during acute and sustained hypoxia (34, 35) . The hypothesis we were testing in the present study is whether the metabolism-lowering effects of acetazolamide might counteract the metabolismincreasing effects of hypoxia. Specifically, we tested if lowdose acetazolamide (which is know to be clinically effective in AMS prevention) mitigates the elevated CMR O 2 associated with cerebral hypoxia in the acute setting (before any onset of AMS) and if this in turn might improve cerebral tissue oxygenation (Pti O 2 ).
Using MRI, we measured cerebral blood flow (CBF), and venous O 2 saturation in the superior sagittal sinus (Sv O 2 ), and from these we determined CMR O 2 and cerebral tissue Pti O 2 responses to acetazolamide during 6 h of normobaric hypoxia.
METHODS

Subjects
Six healthy, nonsmoking, sea-level residents age 35 Ϯ 9 yr (2 females, 4 males) participated in the study. Ethical approval for these studies was granted by the Human Research Protection Program of the University of California, San Diego. Participants were informed of the experimental procedures and possible risks involved in the study, and written informed consent was obtained before participation.
Study Design
The impact of acetazolamide on CBF, CMR O 2 , and PtiO 2 , was evaluated during normoxia and following 6 h of normobaric hypoxia. Baseline MRI measurements were made during normoxia of steadystate cerebral blood flow (CBF) and steady-state transverse relaxation (T 2) in superior sagittal sinus blood [from which we calculated venous oxygen saturation (Sv O 2 )]. Additional measurements were also made of hemoglobin (Hb) concentration, hematocrit (Hct), and pulse oxi-meter measurements of arterial hemoglobin O2 saturation (SaO 2 ). From these measurements we determined steady-state CMRO 2 (35) . By incorporating these data into a diffusion model of O2 transport, we calculated the partial pressure of tissue oxygen in the brain (PtiO 2 ) (4). The measurements were repeated following 6 h of acute normobaric hypoxia at SaO 2 ϳ85% (Fig. 1) . These normoxic and hypoxic measurements were repeated on a subsequent day, following prophylaxis with oral acetazolamide. We chose the lowest clinically effective dose of acetazolamide for prophylaxis (250 mg; Refs. 1, 19, 24, 42) administered as a divided dose of 125 mg ϳ2 h before the baseline MRI scan and 125 mg ϳ3 h before the hypoxic MRI scan.
Acute Hypoxia Paradigm
Within the MRI scanner subjects breathed a premixed 90-Torr hypoxic mixture (12.5% O 2, balance N2) via a close-fitting lowdeadspace nonrebreathing mask (Hans Rudolph 7900/2600, Kansas City, MO). Thirty minutes were included before the MRI measurements for subjects to acclimate to the mask. For the 6-h hypoxic exposure outside the scanner, the close fitting masks were poorly tolerated (and precluded subjects from drinking or eating). Instead, subjects breathed nitrogen-enriched air via a nonrebreathing loosefitting Venturi mask (Hudson, Temecula, CA), and gas flow rate was adjusted to maintain a stable Sa O 2 at ϳ85% (FICO 2 ϳ0.12-0.13). Since we did not have ambulatory O2 monitoring to specifically target FIO 2 , we monitored SaO 2 as a surrogate. The main motivation for this additional setup was to improve subject comfort and compliance. The lighter weight mask was better tolerated by subjects for prolonged periods and improved Sa O 2 stability during the hypoxic exposure.
Physiological Measurements
Arterial O2 saturation was continuously measured using a Nonin 3100 Wrist Pulse Oximeter (during the 6-h hypoxia exposure between MRI measurements) and a Nonin 8600FO MRI-compatible pulse oximeter (Nonin Medical, Plymouth, MN; during MRI measurement). Inspired and expired partial pressures of O 2 and CO2 were continuously monitored during MRI measurements using a Perkin Elmer 1100 medical gas spectrometer (Perkin Elmer, Waltham, MA). Hct and Hb were determined from a venous blood sample; Hb was measured with an IL-682 co-oximeter (Instrument Laboratories, Lexington, MA). Hematocrit was determined from direct measurements of packed cell height in a capillary tube following centrifuging. To ensure that the hypoxic and cardiorespiratory state remained consistent during the steady-state measurements, Sa O 2 and PETCO 2 were compared during CBF and venous T 2 MRI measurements. Imaging sequences were repeated if SaO 2 deviated by more than Ϯ2%, or PETCO 2 deviated by Ϯ2 Torr between these scans.
MRI Measurements
Cerebral blood flow. CBF was measured in gray matter in the cerebrum using a PICORE QUIPPS 2 arterial spin labeling (ASL) technique (TE ϭ 9.1 ms, TR ϭ 2.5 s, TI 1 ϭ 700 ms, TI2 ϭ 1,500 ms, six 6-mm slices, 5 min). Additional images were collected to determine proton density of cerebrospinal fluid and coil sensitivity profile to allow absolute quantitation of CBF from the MRI signal (28, 44, 46) .
Venous T 2 relaxation. T2 was measured in the superior sagittal sinus using a TRUST (T2 relaxation under spin tagging) MRI technique (25) with single shot spiral readout (TE ϭ 2.8 ms, TR ϭ 8 s, TI ϭ 1.2 s, 4 echoes at effective TE 0, 40, 80, and 160 ms, 10-mm slice, 80 mm tag, 4.5 min). Images were acquired just superior to the torcula. The T 2 value was then used to determine venous O2 saturation.
Data Analysis
Cerebral blood flow. Raw ASL data for each subject were corrected for the expected changes in T1 relaxation of blood based on the measured SaO 2 (33) . Images were corrected for cardiorespiratory physiological noise (29) and field inhomogeneities (27) . Resting CBF was averaged across the 5 min of data collection in cerebral gray matter using a mask generated from a separate high-resolution Fast Spoiled GRASS (FSPGR) T 1-weighted 3D anatomical MRI (TE ϭ 4.2 ms, TR ϭ 10.1 ms, TI ϭ 450 ms, bandwidth ϭ 20.83 kHz, field of view ϭ 25 ϫ 25 ϫ 16 cm, matrix 256 ϫ 256 ϫ 128, ϳ1 ϫ 1 ϫ 1.3 mm resolution, 5.5 min). Cerebral gray matter was automatically segmented in the FSPGR scan using FAST software (FMRIB Software Library, Oxford, UK).
Venous oxygen saturation (Sv O 2 ). Cerebral venous O2 saturation was derived from the T2 relaxation of venous blood in the superior sagittal sinus. This uses a simplified Luz-Meiboom model, with a quadratic dependence of T 2 on O2 saturation and hematocrit, which provides a validated method for determining SvO 2 (26, 48) . Calibration scaling constants were determined from a prior normative group (35) .
Cerebral oxygen delivery (DO 2). Cerebral oxygen delivery was calculated based on CBF and O2 content of the arterial blood (Ca). We assumed negligible O2 dissolved in plasma and approximated the Ca by 1.36 ϫ [Hb] ϫ SaO 2 (6) .
Cerebral oxygen metabolism (CMRO 2 ). Cerebral O2 metabolism was calculated using the Fick equation:
where CBF is the cerebral blood flow, OEF is the O2 extraction fraction between arterial and venous blood, (SaO 2 -SvO 2 )/SaO 2 , and Ca is the O 2 content of arterial blood. Since the arterial O 2 content is approximated by the product of SaO 2 and the maximum O 2 content of fully saturated blood, this can be rewritten as:
In this notation, Hb concentration is expressed in units of molar equivalents of oxygen carried per liter of blood when hemoglobin is fully saturated (meq/l) (6) . CBF was calculated from the arterial spin labeled MRI measurements, Sa O 2 from a pulseoximeter, SvO 2 from the sagittal sinus T2 MRI measures, and Hb concentration from a blood sample. CBF is in units of ml·100 ml Ϫ1 ·min Ϫ1 , CMRO 2 is in mol·ml Ϫ1 ·min Ϫ1 (assuming 1 ml tissue/g, this is numerically equivalent to mol·g Ϫ1 ·min Ϫ1 ), and SvO 2 and SaO 2 are in percentages. From these we calculated cerebral O2 metabolism (CMRO 2 ). Subjects then breathed a hypoxic gas mixture that was continually adjusted to maintain SaO 2 at ϳ85% for 6 h (FIO 2 ϭ ϳ0.12-0.13). Subjects breathed a premixed hypoxic gas mixture within the MRI (dashed line) containing 90 Torr O2, and CBF, SvO 2 , and SaO 2 measures were repeated. Measurements were repeated on a subsequent day following a split dose of acetazolamide.
Cerebral tissue oxygenation (PtiO 2 )
. The calculation of cerebral tissue PtiO 2 is based on the theoretical framework proposed by Buxton (4) but modified to include an arterial hemoglobin saturation Ͻ100% (i.e., hypoxic). This model allows us to calculate PtiO 2 from CBF and CMRO 2 given a baseline (normoxic) and challenge (hypoxic) state.
For hypoxia experiments, the measured quantities for the model are fractional arterial hemoglobin saturation, Ya (ϭ %SaO 2 /100) (from pulseoximeter measurements), fractional venous hemoglobin saturation, Yv (ϭ %SvO 2 /100) (from TRUST MRI), and the ratio (f) of CBF during hypoxia to CBF in the baseline normoxic state (from ASL MRI measurements).
The mass balance equation for the ratio (r) of CMR O 2 in the hypoxic state to CMRO 2 in the baseline state is:
The mean capillary PO 2 (PcO 2 ) is taken as the PO2 given by the Hill equation for a saturation halfway between arterial and venous:
A second expression for the metabolic rate ratio r, based on blood/tissue O 2 diffusion is given in Eq. 5 in terms of mean capillary PcO 2 and tissue PtiO 2 during hypoxia and during baseline normoxia (4) . There are several model parameters that must be assumed in addition to the measured parameters. These are baseline tissue PO 2 (PtiO 2,0 ), the PO2 for 50% saturation of hemoglobin (P50), and the Hill exponents (h). These assumed values are Pti O 2,0 ϭ 25 mmHg, P50 ϭ 26 mmHg, and h ϭ 2.8 (4).
Statistical Analysis
Data were analyzed with repeated measures ANOVA of our primary outcome variables (CMR O 2 , CBF, DO2, PETCO 2 , SaO 2 , SvO 2 , PtiO 2 ), with two repeated measure groupings (hypoxic exposure, acetazolamide prophylaxis), each at two levels (normoxia, 6-h hypoxia, no acetazolamide, acetazolamide) (StatView 5.0.1; SAS Institute, Cary, NC). This paired approach allowed each subject to act as his or her own control, which provided greater statistical power to detect small changes. Post hoc power was calculated using G*Power (G*Power 3.1.3; Heinrich Heine University, Dusseldorf, Germany). Data are expressed as mean (SD). Changes were significant at P Ͻ 0.05 two tailed.
RESULTS
All six subjects completed the study. The results are summarized in Tables 1 and 2 (Fig. 2) . Both CBF and CMR O 2 were significantly increased during hypoxia. There was no significant change in DO 2 during hypoxia. The net effect of this was a significant decline in estimated Pti O 2 during hypoxia (Fig. 3) . Primary outcome variables are summarized as mean (SD) and 95% confidence intervals (CI) for each experimental session and are defined as follows: sao2Ϸ, arterial O2 saturation; SvO 2 , venous O2 saturation; PETCO 2 , end-tidal partial pressure of CO2; CBF, cerebral blood flow; DO2, O2 delivery; OEF, oxygen extraction fraction; CMRO 2 ,cerebral oxygen metabolic rate, PtiO 2 , O2 partial pressure in cerebral tissues. The data were analyzed using two-way repeated measures ANOVA with 2 grouping variables, each at 2 levels: 1) normoxia vs. 6-h hypoxia; and 2) treatment with acetazolamide (Rx-Az) vs. no treatment (no-Rx). The P values for the main effect of hypoxia (P hypoxia), main effect of acetazolamide (P Rx), and hypoxia ϫ acetazolamide interaction (P hypoxia ϫ Rx) are reported only for statistical significant results (P Ͻ 0.05). Additional post hoc statistical analysis is included in the relevant figure legends. Note: PtiO 2 for normoxia, no-Rx are reference values (4) so no SD are reported.
Effect of Acetazolamide in Normoxia and Hypoxia
To assess the effect of acetazolamide, data were analyzed with and without acetazolamide prophylaxis for normoxia and hypoxia conditions. In normoxia, acetazolamide had no significant effect on all physiological variables measured. In hypoxia, prophylactic acetazolamide had no significant effect on Sa O 2 , Sv O 2 , Sa O 2 -Sv O 2 , but there was a trend towards decreased PET CO 2 (P ϭ 0.089, post hoc t-test) (Fig. 2) . Acetazolamide prevented the hypoxia-related increases in both CMR O 2 and CBF, which resulted in a decrease in DO 2 (Fig. 3) . The relative reduction in CMR O 2 exceeded the reduction in DO 2 , thus improving cerebral Pti O 2 during hypoxia (Fig. 3B) .
DISCUSSION
Hypoxia stimulates ventilatory drive via its effect on the peripheral chemoreceptors. This stimulated increase in alveolar ventilation also reduces Pa CO 2 (itself a potent ventilatory stimulant); thus the resulting hypocapnia and respiratory alkalosis limit the potential magnitude of any hypoxia-driven increase in ventilation and hence limit the potential to increase arterial oxygenation. The established view of the therapeutic effect of acetazolamide in hypoxia is a renally mediated metabolic acidosis with an enhancement in minute ventilation and oxygenation that would otherwise be limited by hypocapnia (22, 37) .
Cerebral Hemodynamic and Metabolic Responses During Acute Hypoxia
In the current study, we observed that CMR O 2 increased moderately (16%) during 6 h of hypoxia with concurrent increase in CBF. This is consistent with previous studies showing that CMR O 2 and CBF increase during acute and sustained hypoxic hypoxia (34, 35, 47) . In addition, we observed a significant decrease in tissue Pti O 2 during hypoxia (to 54% of normoxia level), and no change in OEF or O 2 delivery (DO 2 ). This mirrors previous findings during prolonged (Ͼ10 h) hypoxia in human subjects and animal experiments (36, 45) .
Acetazolamide Effect on CBF
Literature reports of the effect of acetazolamide on CBF show considerable variation (reviewed by Ref. 22) , with increases (2, 3, 8) , no change or decreases in CBF (16, 36) . Investigators who reported increases in CBF only used higher Primary outcome variables are summarized as mean (SD) and 95% confidence intervals (CI) for each experimental session. doses of acetazolamide (750 mg to 1 g) given intravenously with measurements of CBF made within 15-30 min at the height of very high plasma concentrations of the drug rather than a more clinically applicable lower orally administered dose used in the current study and conventionally for AMS prophylaxis (250 mg, i.e., ϳ3 mg/kg). In fact, Grossmann and Koeberle (13) observed a linear dose-response in CBF which increased from 5 mg/kg up to 20 mg/kg iv of acetazolamide administration, but no significant CBF change with lower doses (Ͻ 5 mg/kg even given iv). We also found that low-dose acetazolamide did not change CBF during normoxia, but it did decrease the otherwise elevated CBF during acute hypoxia. Selective inhibition of carbonic anhydrase subtypes in different tissues likely contributes to these results; The more abundant type II carbonic anhydrase, which is mainly located in erythrocytes (20) , is not inhibited at low doses of acetazolmide, so it is still fully functional in the vasculature. Type IV carbonic anhydrase on the endothelium of cerebral capillary beds (11) , is completely inhibited by even very low doses of acetazolamide, leading to cerebral tissue CO 2 retention and increases the cerebrospinal fluid PCO 2 by ϳ1-2 mmHg (21, 41) . This is sufficient to drive up alveolar ventilation since central chemoreceptors are highly sensitive to CO 2 changes in the cerebrospinal fluid (22) , which then result in ventilatory hypocapnia (36) . Since erythrocyte type II carbonic anhydrase is still active, direct vasodilation is not a primary effect with low-dose acetazolamide (13) , and the overall result is a decrease in CBF due to the hypocapnic vasoconstriction.
Acetazolamide Effect on CMR O 2
The sensitivity of CMR O 2 to hypoxic hypoxia and to the effects of low-dose acetazolamide suggests CO 2 and local tissue pH play an important role in regulating O 2 metabolism. Tissue CO 2 indirectly stimulates adenosine generation in the brain via a reduction in extracellular pH, which suppresses neuronal firing (7) . Changes in pH from carbonic anhydrase inhibition have also been shown to reduce neuronal excitability (23) . We hypothesize that the increased CMR O 2 observed during hypoxia in the current study might also represent adenosine-mediated modulation in neuronal excitability. Hypoxiainduced hyperventilation will decrease Pa CO 2 , and ultimately reduce PCO 2 in cerebral tissues, thus reducing CO 2 -mediated neuronal suppression and increasing neural excitability and oxygen utilization. Low-dose acetazolamide selectively inhibits cerebral endothelial carbonic anhydrase, which leads to an increase in cerebral tissue PCO 2 . This in turn will impact cerebral adenosine generation and limit CMR O 2 . This mechanism is supported by recent studies demonstrating that the 
-test).
This was accompanied by a 16% increase in CMRO 2 (P ϭ 0.03, psot hoc paired t-test). Since O2 delivery was not significantly changed (P ϭ 0.328), this resulted in a 54% decrease in cerebral tissue PtiO 2 (P Ͻ 0.001, post hoc paired t-test). When acetazolamide was administered before the hypoxic exposure, the hypoxic CBF elevation was prevented, and CBF remained unchanged relative to normoxia levels (P ϭ 0.36). The hypoxic rise in CMRO 2 , was also prevented and in fact showed a small decrease of 4.7% (although not significantly different from normoxia, P ϭ 0.42). Acetazolamide also reduced the variance in CMRO 2 during hypoxia between subjects. O2 delivery during hypoxia was also lower with acetazolamide treatment (P ϭ 0.013). The decline in cerebral PtiO 2 during hypoxia was partially mitigated in the presence of acetazolamide (P ϭ 0.007 relative to no acetazolamide). This improvement in cerebral tissue PtiO 2 by acetazolamide during hypoxia was primarily due to its impact in reducing CMRO 2 , which outweighed the decline in O2 delivery. Error bars indicate Ϯ 1 SD. Dashed lines are 95% confidence limits.
hypoxia-induced rise in CMR O 2 can be partially mitigated during isocapnic hypoxia by maintaining PET CO 2 at normoxia levels (34) . Elevating PET CO 2 during hypoxia also mitigates many of the cerebral symptoms associated with acute mountain sickness (14, 17) . The pH sensitivity of phosphofructo-1-kinase, an important rate-limiting step in glycolysis, offers an additional pathway for reducing O 2 consumption, (10) .
Acetazolamide Effect on Pti O 2
Selective inhibition of carbonic anhydrase by low-dose acetazolamide also impacts cerebral tissue oxygenation. A secondary outcome of preventing the rise in CBF during hypoxia by low-dose acetazolamide is a decrease in O 2 delivery to the brain. On the face of it, this does not appear to be a positive effect of acetazolamide prophylaxis. However, the reduction in CMR O 2 by acetazolamide exceeds the reduction in O 2 delivery, which reduces the degree of cerebral tissue Pti O 2 decline otherwise present in hypoxia. In a study examining cerebral oxygenation during exercise in trekkers at high altitude, Vuyk et al. (43) observed a reduction in cerebral oxygenation measured by near-infrared spectroscopy (NIRS). Following acetazolamide the cerebral oxygenation increased. The increase in cerebral oxygenation exceeded the expected increase from just improved arterial oxygenation due to ventilation (37, 43) . This finding supports our proposed mechanism of acetazolamide altering both the delivery and utilization of oxygen in hypoxia.
Measurement Limitation
PET CO 2 might not accurately reflect the underlying Pa CO 2 after acetazolamide. Consistent with this notion is a recent study at high altitude, which showed the increase in Pa CO 2 (ϳ4 mmHg) is greater than that in PET CO 2 (ϳ1 mmHg) after acetazolamide administration (9) . The current study did not include separate arterial blood gas measurements. Thus our measurement of PET CO 2 following acetazolamide may in fact underrepresent the actual changes in Pa CO 2 .
Another potential limitation in our experimental design is the timing of the acetazolamide dose. We gave this as a divided dose to maintain a more constant plasma concentration and limit side effects. One-hundred and twenty-five milligrams were taken 2 h before the first (normoxic) MRI. Six hours later, a second 125-mg dose was taken ϳ3 h before the second (hypoxic) MRI. Oral acetazolamide has an absorption half-life of ϳ1 h, so maximum concentration may take up to ϳ4 h after ingestion (30) . Thus the degree of carbonic anhydrase inhibition could be less complete during the first MRI scan. Due to logistical constraints, the ordering of the normoxia/hypoxia MRI studies was fixed with the normoxia measurements occurring first. Thus this difference in carbonic anhydrase inhibition primarily impacted the normoxia measurements. The conclusions of this study thus focus on the more prolonged acetazolamide effects during the hypoxia measurements.
Our conclusions from these studies are impacted by the assumptions underlying our modeling of Pti O 2 (reviewed in Ref. 4) . Our model for Pti O 2 assumed that increases in cerebral perfusion do not involve additional capillary recruitment (12) . The Pti O 2 calculation also assumed a constant oxygen-hemoglobin dissociation curve (4); however, the acidosis due to acetazolamide could cause a significant right shift in the dissociation curve, and this in turn would increase the capillary PO 2 and the tissue PO 2 . We observed ϳ3 mmHg decline in PET CO 2 with acetazolamide after 6 h of hypoxia, which is within the expected range for this low-dose (selective carbonic anhydrase inhibition) regimen (31). We did not make independent measurements of arterial pH in this study, but estimates of the effect on pH from the two 125-mg acetazolamide doses in normal human subjects would be a decrease from 7.4 to 7.33 during the second (hypoxic) MR measurement (39) . We calculated that this decrease in pH would actually result in a higher Pti O 2 of 19.2 mmHg (15, 32) . Thus assuming a constant oxygen dissociation curve does not affect our primary finding of an improvement in tissue Pti O 2 during hypoxia with acetazolamide prophylaxis, although the true magnitude of this effect may in fact be ϳ16% greater than we present here.
Conclusion
Within the limits of our models discussed above, the primary findings of this study are that low-dose oral acetazolamide, when given prophylactically, attenuates the rise of CMR O 2 during hypoxia and thus improves cerebral tissue oxygenation. This suggests a potentially important role played by cerebral CO 2 and pH in modulating CBF, CMR O 2 , as well as Pti O 2 during hypoxia.
This mode of action of acetazolamide in altering both cerebral O 2 delivery and O 2 utilization and hence preserving tissue oxygenation during hypoxia may be an important mechanism underlying the prophylactic effect of acetazolamide on acute mountain sickness and warrants further investigation.
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